• 繁

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Cigna Group (CI) Evernorth Growth Draws Focus, Is The Stock Still Undervalued?

    Simply Wall St·10/25/2026 13:27:44
    語音播報

    Cigna Group (CI) is back in focus after its Evernorth Health Services unit reported significant revenue and earnings gains, drawing fresh attention to the stock’s fundamentals at a new 52-week high.

    The recent move to a 52-week high has come after a sharp 12.9% 1-month share price return and a 10.0% year-to-date gain, while Cigna Group’s 5-year total shareholder return of 57.7% points to momentum that has been building over a longer stretch, despite a softer 4.0% total shareholder return over the past year.

    Scan how Cigna Group stacks up against other potential healthcare compounders by reviewing our curated list of 29 high quality undervalued stocks that pair solid balance sheets with robust cash flows.

    Bulls see Cigna Group’s Evernorth engine and recent high as proof the stock still looks inexpensive, while bears point to past highs that preceded weaker returns. Which side does the valuation math lean toward next?

    Most Popular Narrative: 52% Undervalued

    The most widely followed narrative on Cigna Group pegs fair value at $636.28, more than double the recent $306.95 close. This puts a spotlight on whether the market is heavily discounting Evernorth’s cash flows or correctly pricing the risks around regulation, litigation, and leadership change.

    Cigna offers a 55.3% raw discount because the market is not valuing growing earnings in isolation. It is pricing political hostility toward PBMs, restrictions on Express Scripts, uncertainty around automated claims review, declining customer counts, uneven cash conversion, and the possibility that today’s most profitable practices may not remain tomorrow’s permissible ones.

    See why 4 investors see Cigna Group as 52% undervalued.

    Result: Fair Value of $636.28 (UNDERVALUED)

    Still, the FTC settlement around Express Scripts and the unresolved PxDx litigation could both undercut the Cigna Group narrative if outcomes are less favorable than expected.

    Find out about the key risks to this Cigna Group narrative.

    Next Steps

    Cigna Group clearly divides opinion, with strong rewards on one side and real risks on the other, so it pays to check the full picture for yourself. To weigh both the upside potential and the concerns currently on investor radars, start by reviewing the 5 key rewards and 1 important warning sign.

    Looking for more investment ideas beyond Cigna Group?

    If you stop with Cigna Group, you miss a wider field of potential opportunities picked using the same disciplined, fundamentals-first lens investors value most.